Klotho Neurosciences (KLTO) Competitors $0.18 -0.04 (-17.24%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock KLTO vs. BCDA, PRPH, NKGN, INAB, GOVX, EDSA, MEIP, FLGC, EQ, and GELSShould you be buying Klotho Neurosciences stock or one of its competitors? The main competitors of Klotho Neurosciences include BioCardia (BCDA), ProPhase Labs (PRPH), NKGen Biotech (NKGN), IN8bio (INAB), GeoVax Labs (GOVX), Edesa Biotech (EDSA), MEI Pharma (MEIP), Flora Growth (FLGC), Equillium (EQ), and Gelteq (GELS). These companies are all part of the "pharmaceutical products" industry. Klotho Neurosciences vs. BioCardia ProPhase Labs NKGen Biotech IN8bio GeoVax Labs Edesa Biotech MEI Pharma Flora Growth Equillium Gelteq BioCardia (NASDAQ:BCDA) and Klotho Neurosciences (NASDAQ:KLTO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership, community ranking and valuation. Which has preferable earnings & valuation, BCDA or KLTO? Klotho Neurosciences has lower revenue, but higher earnings than BioCardia. BioCardia is trading at a lower price-to-earnings ratio than Klotho Neurosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioCardia$58K178.55-$11.57M-$2.33-0.86Klotho NeurosciencesN/AN/A$1.35M-$0.36-0.55 Is BCDA or KLTO more profitable? Klotho Neurosciences has a net margin of 0.00% compared to BioCardia's net margin of -1,999.77%. Company Net Margins Return on Equity Return on Assets BioCardia-1,999.77% N/A -208.38% Klotho Neurosciences N/A N/A -25.89% Does the MarketBeat Community prefer BCDA or KLTO? BioCardia received 17 more outperform votes than Klotho Neurosciences when rated by MarketBeat users. CompanyUnderperformOutperformBioCardiaOutperform Votes1760.71% Underperform Votes1139.29% Klotho NeurosciencesN/AN/A Do analysts rate BCDA or KLTO? BioCardia presently has a consensus price target of $25.00, indicating a potential upside of 1,150.00%. Given BioCardia's stronger consensus rating and higher probable upside, analysts clearly believe BioCardia is more favorable than Klotho Neurosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioCardia 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Klotho Neurosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders believe in BCDA or KLTO? 20.6% of BioCardia shares are held by institutional investors. Comparatively, 20.1% of Klotho Neurosciences shares are held by institutional investors. 20.0% of BioCardia shares are held by company insiders. Comparatively, 26.7% of Klotho Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more volatility and risk, BCDA or KLTO? BioCardia has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500. Comparatively, Klotho Neurosciences has a beta of -1.1, meaning that its share price is 210% less volatile than the S&P 500. Does the media refer more to BCDA or KLTO? In the previous week, BioCardia had 4 more articles in the media than Klotho Neurosciences. MarketBeat recorded 7 mentions for BioCardia and 3 mentions for Klotho Neurosciences. Klotho Neurosciences' average media sentiment score of 0.14 beat BioCardia's score of -0.05 indicating that Klotho Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCardia 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Klotho Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryBioCardia beats Klotho Neurosciences on 10 of the 16 factors compared between the two stocks. Get Klotho Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for KLTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KLTO vs. The Competition Export to ExcelMetricKlotho NeurosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.56M$2.94B$5.40B$8.49BDividend YieldN/A1.72%5.22%4.11%P/E Ratio-0.5530.9526.7119.93Price / SalesN/A410.01395.44119.84Price / Cash0.95168.6838.2534.62Price / Book-0.093.316.854.59Net Income$1.35M-$72.17M$3.23B$248.19M7 Day Performance-31.36%6.36%5.35%2.21%1 Month Performance26.51%9.80%13.31%16.23%1 Year PerformanceN/A-27.03%17.58%8.00% Klotho Neurosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KLTOKlotho NeurosciencesN/A$0.18-17.2%N/AN/A$5.04MN/A-0.50N/ANews CoverageEarnings ReportGap DownBCDABioCardia2.5949 of 5 stars$2.85+0.4%$25.00+777.2%-66.7%$14.52M$58,000.00-0.6840News CoverageEarnings ReportPRPHProPhase Labs1.8568 of 5 stars$0.34+5.4%N/A-93.7%$14.44M$6.77M-0.27130News CoverageEarnings ReportGap UpNKGNNKGen BiotechN/A$0.32+18.6%N/A-83.6%$14.39M$80,000.00-0.06N/ANews CoveragePositive NewsGap DownINABIN8bio3.2134 of 5 stars$0.16-3.1%$6.00+3,697.5%-87.3%$14.34MN/A-0.2120GOVXGeoVax Labs2.1745 of 5 stars$0.94+1.2%$11.10+1,085.1%-36.2%$14.23M$5.59M-0.2610EDSAEdesa Biotech2.8837 of 5 stars$2.01+1.5%$21.00+944.8%-57.2%$14.12MN/A-1.0720News CoverageEarnings ReportGap DownMEIPMEI Pharma2.1536 of 5 stars$2.10+0.5%N/A-32.3%$13.99M$65.30M-0.37100Analyst ForecastFLGCFlora Growth2.5038 of 5 stars$0.71-5.3%$5.00+604.1%-47.0%$13.80M$59.51M-0.54280Gap DownEQEquillium2.6528 of 5 stars$0.39+0.6%$3.00+676.6%-75.1%$13.80M$41.10M-2.7640Upcoming EarningsGELSGelteqN/A$1.44flatN/AN/A$13.59MN/A0.00N/AGap Up Related Companies and Tools Related Companies BioCardia Competitors ProPhase Labs Competitors NKGen Biotech Competitors IN8bio Competitors GeoVax Labs Competitors Edesa Biotech Competitors MEI Pharma Competitors Flora Growth Competitors Equillium Competitors Gelteq Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KLTO) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Klotho Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Klotho Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
